Testosterone Undecanoate (Injectable): Comprehensive Research Overview

Document Version: 1.0 Last Updated: December 2024 Classification: Research Paper - Hormone Replacement Therapy (Male HRT)

Goal Relevance:

• I want to boost my energy levels and feel more vibrant throughout the day.
• I'm looking to improve my muscle growth and strength as part of my fitness routine.
• I need help managing my low testosterone symptoms, like fatigue and low libido.
• I'm seeking a long-term solution for hormone optimization to support my overall well-being.
• I want to enhance my sexual health and improve my libido and performance.
• I'm interested in finding a treatment that can help with my low testosterone-related mood swings.
• I'm looking for a testosterone therapy option that requires less frequent dosing for convenience.

Goal Archetype Integration

Injectable testosterone undecanoate (Aveed/Nebido) serves as a long-acting testosterone formulation that supports multiple health optimization goals. Understanding how this depot-based TRT integrates with specific objectives helps clinicians and patients align therapy with individual outcomes.

Fat Loss Goals

Primary Mechanisms:

• Increases basal metabolic rate by 5-15% through enhanced lean mass
• Improves insulin sensitivity, reducing fat storage tendency
• Promotes lipolysis through androgen receptor activation in adipose tissue
• Reduces visceral fat accumulation (the most metabolically dangerous fat depot)
• Stable testosterone levels minimize cortisol fluctuations that promote fat retention

Protocol Considerations:

• Long-acting depot provides consistent testosterone exposure without peaks/troughs
• Higher estradiol conversion in obese patients requires monitoring but AI less commonly needed due to stable levels
• Fixed 750 mg dose limits titration; consider alternative formulation if metabolic needs change
• Nebido studies show sustained reduction in waist circumference over 10 years

Expected Outcomes:

• 3-6% reduction in body fat over 6-12 months (with consistent training/nutrition)
• Preferential loss of visceral over subcutaneous fat
• More stable energy levels facilitating consistent exercise adherence

Aveed-Specific Considerations:

• Clinic visits every 10 weeks provide natural check-in points for metabolic monitoring
• Unable to self-adjust dose; weight loss may eventually warrant switch to adjustable formulation

Muscle Building Goals

Primary Mechanisms:

• Direct activation of androgen receptors in skeletal muscle
• Increased nitrogen retention and protein synthesis
• Enhanced satellite cell activation and myonuclear addition
• IGF-1 pathway stimulation (synergistic with GH secretagogues)
• Improved recovery capacity and reduced catabolism
• Stable anabolic environment without peaks/troughs

Protocol Considerations:

• Fixed 750 mg/10 week dosing provides approximately 10.7 mg/day average testosterone release
• Lesser fluctuations compared to cypionate/enanthate may benefit continuous anabolism
• Ensure adequate protein intake (1.6-2.2 g/kg body weight)
• Monitor hematocrit closely as training intensifies oxygen demand; TU has highest polycythemia risk

Expected Outcomes:

• 2-5 lbs lean mass gain in first 6 months (hypogonadal men)
• 10-20% strength increases in major lifts over 12 months
• Improved training recovery and reduced DOMS
• Consistent anabolic state without injection-day fluctuations

Longevity & Healthspan Goals

Primary Mechanisms:

• Maintains bone mineral density (reduces fracture risk 30-50%)
• Preserves lean mass (sarcopenia prevention)
• Supports cardiovascular function
• Cognitive protection through neurosteroid effects
• Reduces all-cause mortality in hypogonadal men (observational data)
• Long-term Nebido data shows sustained benefits over 10+ years

Protocol Considerations:

• Stable levels ideal for older patients who may be sensitive to hormonal fluctuations
• Clinic administration ensures compliance and monitoring
• Higher polycythemia risk (OR 2.9) requires vigilant hematocrit monitoring
• Cannot adjust dose; elderly patients unable to start low and titrate
• 30-minute observation requirement ensures safety monitoring

Expected Outcomes:

• Maintained functional capacity into later decades
• Reduced risk of osteoporotic fractures
• Sustained cognitive function and mood stability
• Improved quality of life metrics with minimal daily burden

Healing & Recovery Goals

Primary Mechanisms:

• Enhanced collagen synthesis in connective tissues
• Improved wound healing through angiogenesis promotion
• Reduced systemic inflammation (lowers CRP, IL-6)
• Accelerated muscle repair post-injury
• Consistent testosterone support without treatment gaps

Protocol Considerations:

• Fixed dosing interval means unable to temporarily increase dose during acute recovery
• Clinic administration may be challenging during post-surgical recovery periods
• Consider temporary supplementation with short-acting testosterone if acute healing boost needed
• Stable levels provide consistent healing environment

Expected Outcomes:

• Steady recovery support without hormonal fluctuations
• Improved response to regenerative therapies (PRP, stem cells)
• Reduced rehabilitation timeline with consistent anabolic support

Convenience & Compliance Goals

Unique to Long-Acting Depot:

Primary Benefits:

• Only 5 injections per year after loading phase
• Eliminates daily/weekly injection burden
• No medication storage at home
• No sharps disposal responsibility
• Eliminates injection technique concerns
• Professional administration ensures proper technique

Ideal Candidates:

• Patients with needle phobia (receive fewer injections overall)
• Those with irregular schedules making weekly injections difficult
• Patients requiring supervised medication administration
• Those who value simplicity over dose flexibility
• Patients with cognitive decline who cannot self-manage therapy
• Travelers or those with lifestyle incompatible with refrigerated medication storage

Considerations:

• Requires healthcare facility visits every 10 weeks
• 30-minute post-injection observation mandatory
• High cost (~$2,000/injection) may limit access
• REMS program requirements add administrative burden

Age-Stratified Dosing Guidelines

Injectable testosterone undecanoate presents unique age-related considerations due to its fixed-dose depot formulation and REMS requirements.

Critical Limitation: Fixed Dosing

Aveed is available only as 750 mg/3 mL. Unlike cypionate/enanthate where dose can be precisely titrated, Aveed offers no dose adjustment options. The only variables are:

• Extending dosing interval beyond 10 weeks if levels too high
• Switching to different formulation if dose needs reduction
• Adding HCG or other agents if fertility/testicular preservation needed

This limitation significantly impacts age-stratified recommendations.

Ages 20-35 Years

Clinical Context:

• Uncommon to require TRT in this age range without clear pathology
• Primary causes: Klinefelter syndrome, testicular injury, pituitary tumors, prior chemotherapy
• Fertility preservation is a MAJOR consideration
• Long-acting depot poorly suited for young patients

Aveed Considerations:

• Generally NOT recommended for this age group
• Fixed high-dose depot provides no flexibility for fertility preservation
• Cannot add HCG effectively with supraphysiological depot levels
• If considering children in future, short-acting formulations with HCG strongly preferred
• Long half-life (20-70 days) means prolonged suppression even after discontinuation

If Aveed Used (exceptional circumstances):

• Must rule out all reversible causes first
• Extensive counseling on fertility implications
• Document informed consent regarding reproductive impact
• Consider sperm cryopreservation before initiation
• Plan for formulation switch if fertility becomes priority

Target Levels: Not applicable (fixed dose); monitor for supraphysiological levels

Ages 35-50 Years

Clinical Context:

• Most common age for TRT initiation
• Mix of primary and secondary hypogonadism
• Often concurrent with metabolic syndrome, obesity
• Career and family considerations for consistent therapy
• Some patients still desire future children

Aveed Considerations:

• May be appropriate for patients who:
  • Have completed family building
  • Value infrequent dosing
  • Have insurance coverage
  • Can accommodate clinic visits every 10 weeks
  • Do not require precise dose titration

Starting Protocol:

• Week 0: 750 mg IM
• Week 4: 750 mg IM
• Week 14+: 750 mg IM every 10 weeks

Key Considerations:

• Fertility discussion mandatory; consider sperm banking
• Higher rates of estradiol conversion (especially if BMI >30)
• Highest polycythemia risk among TRT formulations; baseline hematocrit >50% contraindication
• Sleep apnea screening recommended before initiation
• PSA baseline mandatory

Target Levels: 300-1000 ng/dL (eugonadal range maintained for 10 weeks post-injection)

Ages 50-65 Years

Clinical Context:

• "Late-onset hypogonadism" increasingly common
• Often overlaps with cardiovascular disease, diabetes
• Prostate health becomes primary concern
• Balance symptom relief with safety monitoring
• Compliance often improves with infrequent dosing

Aveed Considerations:

• Reasonable option for appropriate patients
• Benefits: Stable levels, professional supervision, compliance assurance
• Concerns: Cannot start low and titrate; fixed high dose
• Polycythemia risk requires careful monitoring

Protocol:

• Standard loading: Week 0, Week 4, then every 10 weeks
• Consider extending to 12 weeks if testosterone levels elevated at trough
• Cannot reduce dose; only option is interval extension or formulation switch

Key Considerations:

• Mandatory baseline PSA and digital rectal exam
• Cardiovascular evaluation including lipid panel, blood pressure
• More frequent hematocrit monitoring (baseline, 6 weeks, 3 months, then every 10 weeks at injection visit)
• Lower threshold for hematocrit intervention (>52% warrants attention)
• Professional supervision at each injection provides safety check

Target Levels: 300-800 ng/dL (accept lower range if symptomatic improvement achieved)

Ages 65+ Years

Clinical Context:

• Highest benefit-to-risk consideration required
• Concurrent medications likely (drug interactions)
• Reduced renal and hepatic clearance
• Fall prevention and functional independence are key goals
• Cognitive changes may make self-administered therapy difficult

Aveed Considerations:

• Consider carefully on case-by-case basis
• Advantages:
  • Professional administration ensures safety
  • 30-minute observation catches acute reactions
  • No home medication management required
  • Regular healthcare touchpoints
  • Eliminates injection technique concerns
• Disadvantages:
  • Cannot start with conservative low dose
  • Highest polycythemia risk in population already at elevated risk
  • Fixed dose inappropriate for many elderly patients
  • Requires transport to healthcare facility every 10 weeks

Protocol (if appropriate):

• Consider starting with short-acting formulation first to establish tolerance
• If transitioning to Aveed: ensure stable on equivalent dose first
• Standard loading with enhanced monitoring
• May need to extend interval to 12+ weeks based on levels

Key Considerations:

• Extended monitoring during titration period
• Prostate monitoring every 3-6 months initially
• Hematocrit at each injection visit (every 10 weeks)
• Assess fall risk and cognitive function at baseline
• Cardiovascular comorbidities require careful risk-benefit discussion
• Ensure reliable transportation to clinic visits

Target Levels: 300-600 ng/dL (often achieved with extended intervals; lower acceptable if symptomatic improvement)

Age-Stratified Summary: Aveed Appropriateness

Nebido (International) Age Considerations

For patients with access to Nebido (1000 mg/4 mL, every 12 weeks):

Advantages over Aveed:

• Longer interval (12 weeks vs 10 weeks)
• Higher dose provides even more stable levels
• No symptom fluctuations reported
• May be more appropriate for elderly due to longer stability

Dosing:

• Loading: Week 0, Week 6
• Maintenance: Every 12 weeks
• Can extend to 14 weeks if levels elevated

Bloodwork Impact

Injectable testosterone undecanoate produces characteristic patterns in laboratory values that differ from short-acting formulations due to its depot release kinetics.

Expected Hormonal Changes

Testosterone Levels

Pattern: Gradual rise to peak at ~7 days (median; range 4-42 days), then slow decline over 10 weeks

Key Difference from Cypionate/Enanthate:

• Much smaller peak-to-trough variation
• Lesser degrees of fluctuation
• Timing of blood draw less critical (stable levels throughout interval)

Monitoring Protocol:

• Check testosterone at any point during dosing interval (levels relatively stable)
• If checking peak: Day 7-14 post-injection
• If checking trough: Day before next scheduled injection
• Target: Any measurement 300-1000 ng/dL

Free Testosterone

Expected Change: Proportional increase following total testosterone pattern

Monitoring: Check if SHBG abnormal or symptoms discordant with total T levels

Estradiol (E2)

Expected Pattern:

• Gradual increase correlating with testosterone
• Less dramatic peaks than cypionate due to stable T levels
• Typical range on therapy: 25-45 pg/mL

Monitoring Considerations:

• Increased estradiol reported as common side effect
• Less likely to need AI compared to short-acting formulations
• Check at 6 weeks, then as clinically indicated

Dihydrotestosterone (DHT)

Expected Change: Increases proportionally with testosterone

• Typical rise: 50-150% above baseline
• Not routinely monitored unless prostate/hair loss concerns

Hematological Changes (CRITICAL)

Polycythemia Risk: HIGHEST among all TRT formulations

Injectable testosterone undecanoate showed highest odds for elevated hematocrit (OR 2.9; 95% CI 1.7-5.0) compared to other TRT modalities.

Hematocrit Monitoring Protocol

Action Thresholds:

• 50-52%: Monitor closely; may continue
• 52-54%: Consider therapeutic phlebotomy; evaluate for formulation switch
• >54%: Hold TRT, therapeutic phlebotomy, restart with different formulation

Why Higher Risk with TU:

• Sustained elevation without troughs
• Higher peak levels than lower-dose short-acting protocols
• Fixed dose cannot be reduced
• Polycythemia increases MACE/VTE risk 5-fold in first year

Hemoglobin

Expected Change: Increase 1-2 g/dL over first 6 months Target Range: 14-17 g/dL Concern: >17.5 g/dL warrants intervention

Lipid Changes

HDL Cholesterol:

• Often decreases 5-15% initially
• May stabilize or improve over 12+ months
• Monitor at baseline, 6 months, then annually

LDL Cholesterol:

• Variable response; may increase, decrease, or remain stable
• Cardiovascular risk assessment should not rely solely on LDL

Triglycerides:

• Often decrease with testosterone optimization
• May reflect improved metabolic health

Prostate Markers

PSA (Prostate-Specific Antigen)

Expected Change:

• Increased PSA reported with therapy
• Typical rise: 0.3-0.5 ng/mL in first year
• Should stabilize after 12-18 months

Monitoring Protocol:

• Baseline mandatory
• 3 months post-initiation
• 6 months
• Then annually minimum (every 6 months if elevated or risk factors)

Concerning Changes:

• PSA >1.4 ng/mL increase in first year
• PSA >4.0 ng/mL (or >3.0 ng/mL if high-risk)
• PSA velocity >0.75 ng/mL/year
• Any change prompting clinical suspicion

Prostate Size

• Digital rectal exam at baseline and annually
• Testosterone may modestly increase prostate volume
• Report new urinary symptoms promptly

Metabolic Markers

Fasting Glucose and HbA1c

Expected Change:

• Improved insulin sensitivity
• Fasting glucose may decrease 5-15 mg/dL
• HbA1c may improve 0.3-0.6% in diabetic/prediabetic patients

Clinical Implication: Diabetic patients may need insulin/oral hypoglycemic dose reduction

Liver Function Tests (LFTs)

Expected Change: No significant hepatic impact expected

• ALT, AST, bilirubin should remain stable
• Injectable TU avoids hepatotoxicity unlike oral methyltestosterone

Monitoring: Baseline, 6 months, then annually

Gonadotropin Suppression

LH (Luteinizing Hormone) and FSH (Follicle-Stimulating Hormone)

Expected Change:

• Profound suppression to undetectable or near-undetectable levels
• Occurs within 2-4 weeks of first injection
• Remains suppressed throughout therapy
• Testicular atrophy occurs from LH/FSH suppression

Clinical Implication:

• Fertility significantly impaired
• Testicular volume decreases without HCG
• Cannot be used to monitor hypogonadism etiology once started

Bloodwork Timing Protocol for Aveed

Recommended Lab Schedule:

Comparison: Bloodwork Timing vs Short-Acting Esters

Protocol Integration: Long-Acting TU vs Short-Acting Formulations

This section addresses how injectable testosterone undecanoate integrates with overall TRT strategy and when it represents the optimal choice versus alternatives.

Understanding the Clinical Niche

Aveed/Nebido occupies a specific position in TRT options:

When to Choose Aveed Over Cypionate/Enanthate

Strong Indications for Long-Acting TU:

1. Compliance Concerns:

   • History of poor medication adherence
   • Cognitive impairment affecting self-administration
   • Lifestyle incompatible with frequent injections
   • Chaotic schedule preventing consistent dosing

2. Needle Phobia (Paradoxically):

   • Patient receives 5 injections/year vs 52-104/year
   • Professional administration reduces anxiety
   • Despite larger needle, fewer total exposures

3. Preference for Professional Oversight:

   • Desire for healthcare touchpoints
   • History of substance misuse requiring supervised administration
   • Comfort with clinic-based care model

4. Insurance/Financial Considerations:

   • Some insurance covers Aveed but not compounded testosterone
   • Copay assistance programs may reduce out-of-pocket cost
   • Copay programs can reduce cost to $0-$300/injection

5. Clinical Stability:

   • Well-established on TRT, stable levels documented
   • No need for ongoing dose adjustments
   • Completed fertility goals

Weak or Contraindicated for Long-Acting TU:

1. Fertility Preservation Required:

   • Cannot effectively combine with HCG
   • Long half-life prolongs suppression after discontinuation
   • Sperm recovery may take 6-12+ months

2. Dose Flexibility Needed:

   • Patients sensitive to testosterone fluctuations
   • Those requiring precise titration
   • Elderly patients who should start low

3. Polycythemia Risk:

   • Baseline hematocrit >50%
   • History of polycythemia on other TRT
   • Highest risk formulation for hematocrit elevation

4. Cost Constraints:

   • $8,000-10,000/year without insurance
   • Even with copay assistance, may exceed alternatives

5. Access Limitations:

   • Unable to attend clinic every 10 weeks
   • Rural location without REMS-certified provider
   • Travel schedule incompatible with fixed appointments

Transitioning Between Formulations

From Cypionate/Enanthate to Aveed

Rationale: Patient desires less frequent dosing, has stable levels, insurance covers Aveed

Protocol:

1. Document stable testosterone levels on current regimen (3+ months)
2. Ensure current dose approximates Aveed equivalent (~100 mg/week cypionate ≈ Aveed)
3. Administer first Aveed injection at time of next scheduled cypionate injection
4. Loading dose: Second injection at Week 4
5. Maintenance: Every 10 weeks thereafter
6. Check levels at Week 6 and Week 14 to confirm adequate replacement
7. Monitor hematocrit more frequently during transition (higher risk with TU)

Caution: Patient may experience different symptom profile due to level stability change

From Aveed to Cypionate/Enanthate

Rationale: Cost, need for dose adjustment, polycythemia, fertility desire

Protocol:

1. Time last Aveed injection
2. Wait until testosterone levels decline to near-trough (typically Week 8-10)
3. Begin cypionate/enanthate at equivalent dose (~100 mg/week)
4. Check levels at Week 4 to confirm transition adequate
5. Titrate as needed based on symptoms and levels
6. Hematocrit may improve with transition to short-acting formulation

REMS Program Considerations

The Aveed REMS Program creates unique requirements that affect protocol integration:

Provider Requirements:

• Must complete REMS certification
• Must have emergency equipment and trained personnel on-site
• Must observe patient for 30 minutes post-injection
• Must document each administration in REMS system

Setting Requirements:

• Healthcare setting must be REMS-certified
• Cannot delegate to non-certified settings
• Home administration prohibited regardless of patient capability

Clinical Impact:

• Limits prescribers to those willing to complete certification
• May reduce access in rural areas
• Adds administrative burden to each visit
• Creates liability considerations for practices

Integration with Other Therapies

Aveed + HCG

Challenge: Fixed high-dose depot makes HCG less effective for testicular preservation

If Attempted:

• HCG 500-1000 IU 2-3x/week may partially maintain testicular function
• Estradiol management becomes more complex
• Less effective than HCG + adjustable-dose cypionate
• Consider for testicular cosmetic concerns rather than fertility

Recommendation: If fertility desired, switch to cypionate + HCG protocol

Aveed + Aromatase Inhibitors

Generally Not Needed:

• Stable testosterone levels produce less E2 spiking
• Increased estradiol reported but typically manageable
• AI use rare with long-acting depot

If AI Required:

• Standard dosing: Anastrozole 0.25-0.5 mg twice weekly
• Monitor E2; avoid over-suppression
• More likely needed in obese patients or those with HCG

Aveed + GLP-1 Agonists

Rationale: Weight loss, metabolic improvement

Integration Considerations:

• Both require healthcare visits (though different schedules)
• Aveed dose cannot be reduced as body fat decreases
• Monitor testosterone levels after significant weight loss (>10% body weight)
• Patient may eventually transition to lower-dose cypionate as metabolic health improves
• Synergistic metabolic benefits

Aveed + Growth Hormone Peptides

Rationale: Body composition optimization

Integration:

• Compatible combination
• No direct interactions
• Both support anabolic environment
• Monitor IGF-1 and hematocrit (both can affect erythropoiesis)
• GH peptides typically dosed at bedtime; Aveed administered at clinic

Cost-Benefit Analysis: Aveed vs Alternatives

Annual Cost Comparison:

Value Proposition:

• If insurance covers Aveed with low copay: Excellent value for appropriate patients
• If paying out-of-pocket: Rarely cost-effective vs alternatives
• Convenience value highly individual (some patients gladly pay premium for infrequent dosing)

Protocol Selection Flowchart

Is fertility a current or future consideration?
├── YES → Cypionate + HCG (not Aveed)
└── NO → Continue

Is baseline hematocrit >50%?
├── YES → Cypionate with close monitoring (not Aveed)
└── NO → Continue

Does patient require dose flexibility?
├── YES → Cypionate/Enanthate
└── NO → Continue

Can patient comply with weekly injections?
├── NO → Aveed may be appropriate
└── YES → Continue

Is Aveed covered by insurance?
├── YES → Consider Aveed
├── NO, but patient prefers convenience → Aveed if affordable
└── NO, cost is concern → Cypionate/Enanthate

1. Executive Summary + Regulatory Classification

Overview

Injectable testosterone undecanoate (Aveed) is a long-acting depot formulation that provides sustained testosterone replacement therapy with dosing intervals of every 10 weeks after initial loading doses. Approved by the FDA on March 5, 2014, Aveed represents a significant advancement in TRT convenience, offering the longest dosing interval of any FDA-approved testosterone product.

However, Aveed's approval came after 3 previous FDA rejections due to serious safety concerns. The product carries a black box warning for pulmonary oil microembolism (POME) and anaphylaxis, and is available only through a mandatory Risk Evaluation and Mitigation Strategy (REMS) program.

Chemical Name: Testosterone undecanoate (4-androsten-17β-ol-3-one 17-undecanoate) CAS Number: 5949-44-0 Molecular Formula: C₃₀H₄₈O₃ Molecular Weight: 456.71 g/mol

Primary Indications

• FDA-Approved Use: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary hypogonadism [congenital or acquired] and hypogonadotropic hypogonadism [congenital or acquired])

FDA-Approved Injectable Testosterone Undecanoate Product

Note: Nebido is marketed in over 80 countries including Europe, Australia, and Canada, but injectable testosterone undecanoate only became available in the United States in 2014 as Aveed.

Regulatory Classification

Key Advantages

• Longest dosing interval: Every 10 weeks after loading doses
• Minimal fluctuations: Lesser degrees of testosterone level fluctuations vs cypionate/enanthate
• High efficacy: 94% of patients achieve normal testosterone levels (300-1000 ng/dL)
• Long duration: Sustained therapeutic levels for 10 weeks

Key Disadvantages

• REMS program: Must be administered in certified healthcare setting with 30-minute post-injection observation
• POME risk: Serious pulmonary oil microembolism can occur after any injection
• Anaphylaxis risk: Life-threatening allergic reactions reported
• Large injection volume: 3 mL castor oil causes patient discomfort
• Cost: ~$2,000 per injection (brand name only, no generic)
• Clinic-only administration: Cannot self-administer at home

2. Chemical Structure & Pharmacology

Molecular Structure

Testosterone undecanoate is an esterified derivative of testosterone where the 17β-hydroxyl group is esterified with undecanoic acid (11-carbon fatty acid chain).

Testosterone: C₁₉H₂₈O₂ (288.42 g/mol) + Undecanoic acid (C₁₁H₂₂O₂) → Testosterone undecanoate: C₃₀H₄₈O₃ (456.71 g/mol)

The long-chain undecanoate ester makes the compound highly lipophilic, enabling slow release from the castor oil depot.

Depot Formulation Composition

Aveed (US Formulation)

Active ingredient: Testosterone undecanoate 750 mg / 3 mL (250 mg/mL)

Inactive ingredients:

• Castor oil (refined): 885 mg - Oil vehicle creating depot
• Benzyl benzoate: 1,500 mg - Solubilizing agent and preservative

Storage: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)

Nebido (International Formulation)

Active ingredient: Testosterone undecanoate 1000 mg / 4 mL (250 mg/mL)

Inactive ingredients: Same castor oil and benzyl benzoate formulation

Key difference: Higher dose (1000 mg vs 750 mg) allowing longer dosing intervals (12 weeks vs 10 weeks).

Depot Mechanism

The castor oil vehicle creates an intramuscular depot from which testosterone undecanoate is slowly released into systemic circulation. The lipophilic ester partitions into the oily depot, providing sustained release over weeks to months.

3. Mechanism of Action (Tissue-Specific)

Ester Hydrolysis and Testosterone Release

Once absorbed from the castor oil depot, testosterone undecanoate is hydrolyzed by esterases to release free testosterone and undecanoic acid. Free testosterone then exerts biological effects through androgen receptor (AR) binding.

Androgen Receptor Activation

Testosterone binds to cytoplasmic androgen receptors, which then translocate to the nucleus, bind to androgen response elements (AREs) on DNA, and regulate gene transcription.

Tissue-Specific Effects

Direct testosterone action:

• Muscle tissue: Protein synthesis, muscle mass, strength
• Bone: Increased bone mineral density
• Brain: Mood, cognition, libido
• Adipose tissue: Lipolysis, reduced visceral fat
• Erythropoiesis: Red blood cell production

5α-Reductase conversion to DHT (2.5× more potent):

• Prostate: Growth and secretory function
• Skin: Sebaceous gland activity, acne
• Hair follicles: Androgenic alopecia, body/facial hair growth

Aromatase conversion to estradiol:

• Bone: Epiphyseal closure, bone density maintenance
• Brain: Mood regulation, neuroprotection
• Breast tissue: Gynecomastia at supraphysiological levels

4. Pharmacokinetics & Formulation Comparison

Absorption from Depot

Time to peak concentration: Following 750 mg IM injection, serum testosterone reaches maximum after median 7 days (range 4-42 days), then slowly declines over 10 weeks.

Depot release kinetics: The castor oil depot provides sustained testosterone release. Testosterone undecanoate was nearly undetectable 42 days following injection, indicating complete ester hydrolysis by 6 weeks.

Steady State

Serum testosterone concentration reached steady state after the third injection when first and second injections were administered at weeks 0 and 4.

Timeline to steady state:

• Week 0: First injection (750 mg)
• Week 4: Second injection (750 mg)
• Week 14: Third injection (750 mg) → Steady state achieved
• Trough values of free testosterone, SHBG, DHT, and E2 remained relatively consistent after week 14

Elimination Half-Life

Elimination half-life of testosterone undecanoate: 20.9 days in tea seed oil, 33.9 days in castor oil

Clinical studies report varying values:

• 18.3 ± 2.3 days for 500 mg dose; 23.7 ± 2.7 days for 1000 mg dose
• Terminal half-life of 25.7 ± 4.0 days
• Prolonged treatment: approximately 70.2 days

Practical implication: Long half-life supports 10-week dosing intervals without subtherapeutic testosterone levels.

Duration of Effect

Intramuscular injection of 750 mg Aveed generates mean steady-state serum testosterone concentrations in normal range for 10 weeks.

Metabolism

Ester cleavage: Testosterone undecanoate → testosterone + undecanoic acid

Testosterone metabolism:

• 5α-Reductase: Testosterone → DHT (more potent androgen)
• Aromatase (CYP19A1): Testosterone → Estradiol
• Conjugation: Glucuronidation and sulfation to inactive metabolites

Excretion:

• Urine: 90% as conjugates
• Feces: 6%

Formulation Comparison: Aveed vs Nebido

Key difference: Nebido's higher dose (1000 mg) allows 12-week dosing intervals vs Aveed's 10-week intervals.

Comparison with Short-Acting Injectable Testosterone

5. Clinical Dosing Guidelines (FDA-Labeled + Off-Label)

FDA-Approved Dosing Protocol

Loading phase:

• Week 0: 750 mg (3 mL) IM injection
• Week 4: 750 mg (3 mL) IM injection

Maintenance phase:

• Every 10 weeks thereafter: 750 mg (3 mL) IM injection

Site of injection: Deep intramuscular injection into gluteal muscle (buttocks)

Administration requirements:

• Must be administered by healthcare professional certified in Aveed REMS Program
• Observe patient in healthcare setting for 30 minutes after each injection to monitor for POME or anaphylaxis

Nebido Dosing Protocol (International)

Loading phase:

• Week 0: 1000 mg IM
• Week 6: 1000 mg IM

Maintenance:

• Every 12 weeks: 1000 mg IM

Monitoring and Dose Adjustment

Testosterone level monitoring:

• Measure testosterone levels periodically after starting therapy
• Target range: 300-1000 ng/dL (eugonadal)
• Timing: No specific timing requirement (unlike short-acting esters requiring trough measurements)

Dose adjustment: Aveed is available only as 750 mg/3 mL. There is no dose titration option. If testosterone levels are:

• Too low: Consider switching to different TRT formulation
• Too high: Extend dosing interval beyond 10 weeks or switch formulation

Off-Label Use: Gender-Affirming Hormone Therapy

Injectable testosterone undecanoate is rarely used for masculinizing therapy due to:

• REMS program requirements (clinic-only administration)
• Cost (~$2,000 per injection)
• Availability of more affordable options (cypionate/enanthate)

However, for patients who prefer infrequent dosing and have insurance coverage, Aveed/Nebido may be considered.

6. Pivotal Clinical Trials & Evidence

Aveed Phase 3 Pivotal Trial (84-Week Study)

Study design: Single-arm, open-label, multicenter Phase 3 trial

Participants: 130 hypogonadal adult patients

• Mean age: 54 years
• Baseline morning serum testosterone: <300 ng/dL
• Mean screening testosterone: 215 ng/dL

Intervention: Aveed 750 mg IM at week 0, week 4, then every 10 weeks for 84 weeks (9 total injections)

Primary endpoint: Percentage of patients achieving average testosterone concentration within normal range (300-1000 ng/dL)

Results:

• 94% of patients achieved average testosterone concentration within normal range at steady state
• Patients showed increased mean serum testosterone levels and maintained them up to 10 weeks

Safety: Safety and efficacy evaluated through 18 clinical trials worldwide involving over 3,556 subjects

POME and Anaphylaxis Incidence

During adjudication of all cases meeting specific criteria, 9 POME events in 8 patients and 2 anaphylaxis events among 3,556 patients were identified across 18 clinical trials.

Incidence rate:

• POME: <0.1%
• Anaphylaxis: <0.1%

POME events appear to be rare, with resolution occurring quickly without medical intervention in most cases.

Long-Term Safety and Efficacy

Large study bolsters efficacy and safety of long-acting testosterone replacement therapy, demonstrating:

• Sustained eugonadal testosterone levels over 84 weeks
• Stable efficacy without tachyphylaxis
• Safety profile consistent with testosterone therapy class effects

7. Safety Profile + Black Box Warnings

FDA Black Box Warning: POME and Anaphylaxis

All Aveed labeling carries a black box warning:

Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after administration of testosterone undecanoate injection. These reactions can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose.

Clinical presentation of POME:

• Urge to cough
• Dyspnea (difficulty breathing)
• Throat tightening
• Chest pain
• Dizziness
• Syncope (fainting)

Anaphylaxis symptoms:

• Life-threatening allergic reactions
• Requires immediate emergency treatment

Prevention measures:

• Following each injection, observe patients in healthcare setting for 30 minutes
• Healthcare settings must have on-site access to equipment and personnel trained to manage serious POME and anaphylaxis

REMS Program Requirements

The Aveed REMS Program is required by the FDA to mitigate risks of POME and anaphylaxis.

Program requirements:

1. Healthcare providers must be certified with REMS Program before prescribing/administering Aveed
2. Healthcare settings must be certified and have certified providers before ordering/dispensing
3. Settings must have on-site access to emergency equipment and trained personnel
4. 30-minute post-injection observation mandatory

Implication: Aveed cannot be self-administered at home, unlike testosterone cypionate/enanthate.

Common Side Effects

Injection site reactions (most common):

• Injection site pain: 4.6% of patients in 84-week study
• Post-approval reports: Site discomfort, hematoma, irritation

Endocrine/Metabolic:

• Increased estradiol level
• Gynecomastia: 1-3%
• Testicular atrophy (from LH/FSH suppression)

Dermatological:

• Acne
• Oily skin

Hematological:

• Increased red blood cell count
• Polycythemia/erythrocytosis: 3-15%
• Elevated hematocrit

Urogenital:

• Increased prostate-specific antigen (PSA)
• BPH symptoms

Other:

• Fatigue
• Irritability
• Difficulty sleeping
• Mood swings

Serious Adverse Events

Polycythemia

Injectable testosterone formulations produce greatest effect on hemoglobin/hematocrit increases.

Polycythemia incidence: 10.1 per 1000 person-years for injectable testosterone (vs 1.2 for oral).

Long-acting testosterone undecanoate showed highest odds for elevated hematocrit (OR 2.9; 95% CI 1.7-5.0) compared to testosterone gel.

Critical finding: Secondary polycythemia during TRT increases MACE/VTE risk in first year.

Intervention threshold: Hematocrit ≥54% → interrupt therapy, phlebotomy, restart at different formulation

Cardiovascular Risk

Exogenous testosterone may affect blood clotting, polycythemia, and atherosclerosis.

However, systematic review of >50 trials showed testosterone therapy not associated with increased cardiovascular events.

Recent FDA label changes (2025):

• Cardiovascular black box warning removed (based on TRAVERSE trial)
• Blood pressure elevation warnings retained

8. Formulation Options & Administration

FDA-Approved Brand Formulation

Aveed (Endo Pharmaceuticals):

• Strength: 750 mg testosterone undecanoate / 3 mL (250 mg/mL)
• Presentation: Single-use vial
• Cost: ~$2,000 per injection

Generic Availability

No generic formulation available in the United States. Aveed is brand-name only.

International Formulation: Nebido

Nebido (Bayer):

• Strength: 1000 mg / 4 mL (250 mg/mL)
• Availability: Over 80 countries (Europe, Australia, Canada, Asia)
• Not available in US (Aveed is US equivalent)

Administration Technique

Injection site: Deep intramuscular (IM) injection into gluteal muscle

Step-by-step procedure:

1. Patient positioning: Prone or lateral decubitus
2. Site selection: Upper outer quadrant of gluteal muscle
3. Needle: 21-gauge, 1.5-inch needle
4. Volume: Full 3 mL dose administered
5. Aspiration: Aspirate before injection to ensure not in blood vessel
6. Injection: Slow, steady injection of full 3 mL volume
7. Post-injection observation: Patient must remain in healthcare setting for 30 minutes

CRITICAL: Only healthcare professionals certified in Aveed REMS Program may administer.

Patient Discomfort Considerations

Testosterone undecanoate is administered in large volume of oil (3 mL), which causes patient discomfort.

Strategies to minimize discomfort:

• Slow injection technique
• Warm vial to room temperature before injection
• Use appropriate needle length to reach deep gluteal muscle
• Advise patient to relax gluteal muscles during injection

9. Storage & Stability

Storage Requirements

Temperature: Store at 20°C to 25°C (68°F to 77°F)

Excursions permitted: 15°C to 30°C (59°F to 86°F) (USP Controlled Room Temperature)

Protection:

• Protect from light
• Store in original carton until use
• Keep vial in carton to protect from light

Handling:

• Warm to room temperature before administration
• Inspect visually for particulate matter and discoloration before administration
• Do not use if cloudy or particles present

Stability

Testosterone undecanoate in castor oil is stable for duration of product shelf life when stored according to label conditions.

Single-use vial: Discard any unused portion after withdrawal of dose.

10. Detailed Regulatory Status (FDA, DEA, WADA, International)

FDA Approval History

DEA Schedule III Classification

Aveed contains testosterone, a Schedule III controlled substance under the Controlled Substances Act.

Schedule III characteristics:

• Moderate to low potential for physical/psychological dependence
• Medical use accepted in United States
• Examples: Codeine products <90 mg/dose, ketamine, anabolic steroids, testosterone

Prescribing restrictions:

• Prescriptions may be verbal, written, or electronic (EPCS)
• Maximum 5 refills in 6-month period
• Prescription valid for 6 months from date written

REMS additional requirements:

• Prescriber must be certified in Aveed REMS Program
• Only certified healthcare settings may order/dispense Aveed

WADA Prohibited Status

Testosterone and all derivatives are prohibited at all times by WADA.

Classification: Anabolic agent (S1.1 - Anabolic Androgenic Steroids)

All testosterone formulations (oral, injectable, transdermal) are prohibited both in-competition and out-of-competition.

Therapeutic Use Exemption (TUE): Athletes with documented hypogonadism may apply for TUE.

International Regulatory Status

Nebido availability:

• Approved in European Union: 2003
• Available in 80+ countries worldwide
• Europe, Australia, Canada, Asia: Prescription required
• United Kingdom: Prescription-only medicine (POM)
• Not available in United States (Aveed is US equivalent)

11. Product Cross-Reference (Compounding vs Brand)

Brand Name Products: Cost Comparison

Copay assistance available: Eligible patients with commercial insurance may pay $0 copay, with program covering up to $300 per injection. Not valid for Medicare/Medicaid.

Comparison with Other TRT Modalities

Cost comparison: Testosterone cypionate 10mL vial provides 5-month supply for average monthly cost of $18.45, making it 50× more affordable than Aveed.

Generic Injectable Testosterone

No generic testosterone undecanoate available in US.

Generic short-acting injectable testosterone (cypionate, enanthate) widely available at low cost.

Compounded Injectable Testosterone

Testosterone undecanoate is not typically available from compounding pharmacies due to:

• Complexity of castor oil depot formulation
• REMS program requirements
• Liability concerns regarding POME/anaphylaxis risk

Compounding pharmacies offer testosterone cypionate and enanthate as cost-effective alternatives.

12. References & Citations

FDA Approval and Regulatory Documents

1. FDA approves Aveed long-acting testosterone - TransGuys.com 2014
2. FDA approves Aveed with restrictions - Medscape 2014
3. Aveed FDA approval history - Drugs.com
4. Aveed FDA label - 2014
5. Aveed FDA label - 2015 update
6. Aveed FDA label - 2025 update
7. FDA declines approval third time - The Lancet 2013
8. Endo receives FDA approval for Aveed - March 2014

REMS Program and Safety

9. NDA Cross-Discipline Review - FDA 2014
10. Aveed REMS Program website
11. Aveed REMS - Healthcare provider enrollment
12. Occurrence of POME after testosterone undecanoate - PMC
13. DailyMed - AVEED

Clinical Trials and Efficacy

14. Aveed for treatment of hypogonadism - Clinical Trials Arena
15. Aveed clinical data
16. Large study bolsters efficacy and safety - Urology Times

Pharmacokinetics and Dosing

17. Optimal injection interval for TU - PMC
18. Aveed dosing guide - Drugs.com
19. Aveed 750mg solution - Kaiser Permanente
20. Aveed dosing and administration
21. Population pharmacokinetic modeling - PMC
22. Pharmacokinetics and safety: 84-week trial - Wiley
23. Pharmacokinetics of testosterone - Wikipedia
24. Pharmacokinetic study of injectable TU - PubMed
25. Injectable TU has favorable pharmacokinetics - Oxford Academic

Nebido and International Formulations

26. Testosterone undecanoate - Wikipedia
27. Safety aspects of testosterone undecanoate - PMC
28. Testosterone Nebido guide - Balance My Hormones
29. Nebido injection guide - Voy
30. Is Nebido available in USA? - TRT Hub

Side Effects and Safety Profile

31. What to expect with Aveed
32. Aveed uses and warnings - GoodRx
33. Aveed side effects - RxList
34. Side effects of Aveed - MedicineNet

Polycythemia and Cardiovascular Risk

35. Safety aspects and rational use - Dovepress
36. Injection testosterone and adverse CV events - PMC
37. Secondary polycythemia increases MACE/VTE risk - PubMed
38. Erythrocytosis and polycythemia secondary to TRT - ScienceDirect
39. Risk of adverse outcomes with testosterone - PMC
40. Risk of adverse outcomes - PubMed
41. Prevalence and predictive factors of erythrocytosis - Frontiers

Comparative Studies

42. Comparison of testosterone replacement therapy - BYU
43. Long vs short acting testosterone treatments - PMC
44. Injectable testosterone: 3 types explained - GoodRx
45. Which form of testosterone is most effective? - MedicineNet
46. Testosterone replacement therapy options - Men's Health Georgia

Monitoring Guidelines

47. Testosterone deficiency guideline - AUA
48. [Follow-up laboratory testing table - AUA](https://www.auanet.org/documents/Guidelines/PDF/Table Seven - Follow-up Laboratory Testing(0).pdf)
49. Evaluation and management of testosterone deficiency - Journal of Urology

Cost and Pricing

50. Aveed drug information - Hims
51. Aveed copay assistance program
52. Get Aveed - HCP
53. Paying for Aveed - HCP
54. Aveed copay assistance PDF
55. Testosterone undecanoate policy - Aetna

DEA and Controlled Substance Regulations

56. DEA controlled substance schedules
57. DEA drug scheduling
58. Drug enforcement administration drug scheduling - NCBI
59. Federal controlled substances prescriptions - PMC
60. Prescription of controlled substances - NCBI

13. Monitoring & Lab Values

Pre-Treatment Baseline Testing

Required before initiating Aveed:

1. Serum testosterone (total):

   • Two morning samples (7-11 AM) on separate days
   • Diagnosis threshold: <300 ng/dL
   • Confirms hypogonadism diagnosis

2. Complete blood count (CBC):

   • Baseline hemoglobin: Normal 13.5-17.5 g/dL
   • Baseline hematocrit: Normal 38-50%
   • CRITICAL: Patients with hematocrit >50% should delay therapy to avoid polycythemia

3. Prostate-specific antigen (PSA):

   • Baseline PSA in men >40 years
   • Normal: <4.0 ng/mL
   • Abnormal PSA requires urology evaluation before TRT

4. Digital rectal exam (DRE):

   • Men ≥40 years
   • Rule out prostate abnormalities

5. Lipid panel:

   • Total cholesterol, LDL, HDL, triglycerides

6. Liver function tests:

   • ALT, AST, bilirubin

On-Treatment Monitoring Schedule

Testosterone Levels

Initial monitoring:

• Measure testosterone every 4 weeks until stable therapeutic levels reached
• Target range: 280-873 ng/dL (physiologic range)

Long-term monitoring:

• Testosterone levels every 6-12 months once stable
• Maintaining physiologic testosterone range recommended

Timing consideration: Unlike short-acting esters requiring trough measurements, Aveed produces stable levels, so timing of blood draw is less critical.

Hematocrit Monitoring (CRITICAL)

Frequency:

• [Baseline, then 3-6 months after starting, then annually](https://www.auanet.org/documents/Guidelines/PDF/Table Seven - Follow-up Laboratory Testing(0).pdf)
• If elevated, monitor every 3 months in first year, then every 6 months

Action thresholds:

• Hematocrit >50%: Consider withholding therapy until etiology investigated
• Hematocrit ≥54%: [Warrants intervention: dose reduction or temporary discontinuation](https://www.auanet.org/documents/Guidelines/PDF/Table Seven - Follow-up Laboratory Testing(0).pdf)

Rationale: Injectable TU showed highest odds for elevated hematocrit (OR 2.9); polycythemia increases MACE/VTE risk

Prostate Monitoring

PSA:

• Mandatory before and during testosterone therapy
• First year: 3, 6, and 12 months
• Annually in subsequent years
• Concerning changes: PSA >1.4 ng/mL increase in first year, PSA >4.0 ng/mL

DRE: Annually in men ≥40 years

Lipid Panel

• Baseline, then periodically during therapy
• Testosterone may alter lipid profile

Blood Pressure

• Monitor periodically
• Testosterone may increase blood pressure

Post-Injection Monitoring (REMS Requirement)

30-minute observation period mandatory after each injection to monitor for:

• POME symptoms: Cough, dyspnea, throat tightening, chest pain, dizziness, syncope
• Anaphylaxis: Allergic reaction, difficulty breathing, hypotension

Healthcare setting requirements:

• On-site access to emergency equipment and trained personnel
• Ability to manage serious POME and anaphylaxis

14. Drug Interactions & Contraindications

Major Drug Interactions

Oral Anticoagulants (Warfarin)

Interaction mechanism: Testosterone may enhance anticoagulant effect, increasing bleeding risk

Monitoring: More frequent INR and prothrombin time monitoring, especially during initiation/termination of TRT

Clinical significance: HIGH

Insulin and Oral Hypoglycemics

Interaction mechanism: Androgens may decrease blood glucose, necessitating dose reduction of anti-diabetic medication

Monitoring: Frequent blood glucose monitoring; insulin/oral hypoglycemic dose may need reduction

Clinical significance: MODERATE to HIGH

Absolute Contraindications

Aveed is contraindicated in:

1. Men with known or suspected prostate cancer or breast cancer

   • Testosterone may stimulate androgen-responsive tumor growth
   • Patients must be evaluated for prostate cancer prior to initiating and during treatment

2. Women who are or may become pregnant

   • Testosterone may cause fetal harm
   • Risk of virilization of female fetus

3. Women who are breastfeeding

   • Testosterone may transfer to infant via breast milk

Relative Contraindications (Use with Caution)

Severe heart failure (NYHA Class III-IV):

• Fluid retention risk
• Increased cardiovascular workload

Benign prostatic hyperplasia (BPH) with severe symptoms:

• Testosterone may worsen urinary obstruction

Severe sleep apnea:

• Testosterone may exacerbate sleep apnea

Polycythemia (hematocrit >50%):

• Patients should delay therapy until hematocrit normalizes
• Injectable TU has highest polycythemia risk

Special Populations

Pediatric Use

• Not indicated for pediatric populations
• Risk of premature epiphyseal closure

Geriatric Use (≥65 years)

• Increased cardiovascular and prostate cancer risk
• More frequent monitoring required
• Consider alternative TRT formulation with easier dose adjustment

Renal Impairment

• No dose adjustment required (testosterone metabolized hepatically)

Hepatic Impairment

• Use with caution
• Monitor liver function tests

Conclusion

Injectable testosterone undecanoate (Aveed) represents the longest-acting FDA-approved testosterone formulation, offering unprecedented convenience with every-10-week dosing after loading doses. 94% of patients achieve eugonadal testosterone levels with minimal fluctuations compared to short-acting esters.

However, the serious risks of POME and anaphylaxis necessitate a mandatory REMS program, requiring clinic-only administration with 30-minute post-injection observation. These restrictions, combined with high cost (~$2,000 per injection) and highest polycythemia risk among TRT formulations (OR 2.9), significantly limit Aveed's practical use.

Aveed is most suitable for patients who:

• Prioritize minimal injection frequency
• Have insurance coverage or copay assistance
• Accept clinic-only administration
• Are monitored closely for polycythemia
• Do not have contraindications to long-acting depot

For most patients, testosterone cypionate remains more cost-effective ($18.45/month vs $2,000/injection) with home self-administration convenience, while Aveed fills a niche for those requiring infrequent dosing with supervised administration.

Document Prepared By: Research Team, Epiq Aminos Date: December 2024 Total Word Count: ~13,000 words Total Citations: 60 references